Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average) (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Shares Outstanding (Weighted Average) data on record, last reported at $82.2 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 15.56% year-over-year to $82.2 million; the TTM value through Sep 2025 reached $82.2 million, up 15.56%, while the annual FY2024 figure was $73.9 million, 43.8% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $82.2 million in Q3 2025 per GLUE's latest filing, roughly flat from $82.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $82.2 million in Q3 2025 and bottomed at $49.3 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $65.2 million, with a median of $65.7 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 43.8% in 2024, then rose 15.56% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $51.4 million in 2023, then surged by 43.8% to $73.9 million in 2024, then rose by 11.28% to $82.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $82.2 million in Q3 2025, $82.2 million in Q2 2025, and $82.1 million in Q1 2025.